We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+21.74%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.87B
AUM Growth
+$435M
Cap. Flow
+$144M
Cap. Flow %
3.71%
Top 10 Hldgs %
35.18%
Holding
133
New
4
Increased
60
Reduced
11
Closed
5

Top Buys

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$39.2M
2
BPMC
Blueprint Medicines
BPMC
+$35.9M
3
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$21.8M
4
WST icon
West Pharmaceutical
WST
+$21.2M
5
GOSS icon
Gossamer Bio
GOSS
+$19.7M

Top Sells

Rank Stock Value
1
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$64.6M
2
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$20.5M
3
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$15.4M
4
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$14.2M
5
EPZM
Epizyme, Inc
EPZM
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 96.71%
2 Consumer Staples 0.91%
3 Industrials 0.67%
4 Financials 0.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKRO
26
DELISTED
Akero Therapeutics
AKRO
$46.6M 1.2%
1,369,973
+690,459
+102% +$10.6M
HZNP
27
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$45M 1.16%
727,000
-19,000
-3% -$1.33M
WST icon
28
West Pharmaceutical
WST
$24.8B
$44.4M 1.15%
180,500
+69,500
+63% +$21.2M
ASND icon
29
Ascendis Pharma A/S
ASND
$16.8B
$43.9M 1.13%
425,500
– –
RYTM icon
30
Rhythm Pharmaceuticals
RYTM
$7.95B
$43.1M 1.11%
1,760,865
+357,567
+25% +$6.65M
XENE icon
31
Xenon Pharmaceuticals
XENE
$6.21B
$41.7M 1.08%
1,155,961
+32,357
+3% +$1.16M
PRTA icon
32
Prothena Corp
PRTA
$468M
$41.1M 1.06%
678,462
– –
ZLAB icon
33
Zai Lab
ZLAB
$2.65B
$40.8M 1.05%
1,192,400
-23,500
-2% -$1.01M
BAX icon
34
Baxter International
BAX
$14.4B
$40.7M 1.05%
755,500
+53,900
+8% +$3.24M
CINC
35
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$39.6M 1.02%
1,205,856
+184,697
+18% +$5.22M
DXCM icon
36
DexCom
DXCM
$33.1B
$39.5M 1.02%
490,500
+17,700
+4% +$1.5M
RXDX
37
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$38.1M 0.98%
645,407
+900
+0.1% +$41.2K
MIRM icon
38
Mirum Pharmaceuticals
MIRM
$6.02B
$37.7M 0.97%
1,795,733
+78,000
+5% +$1.88M
SGEN
39
DELISTED
Seagen Inc. Common Stock
SGEN
$37.2M 0.96%
272,000
– –
IRTC icon
40
iRhythm Holdings
IRTC
$4.1B
$36.7M 0.95%
293,250
+23,250
+9% +$3.36M
NVRO
41
DELISTED
NEVRO CORP.
NVRO
$36.7M 0.95%
787,000
+13,700
+2% +$636K
FRPT icon
42
Freshpet
FRPT
$3.26B
$35.1M 0.91%
700,000
+62,400
+10% +$2.94M
CVET
43
DELISTED
Covetrus, Inc. Common Stock
CVET
$35.1M 0.91%
1,678,800
– –
PHR icon
44
Phreesia
PHR
$769M
$33.2M 0.86%
1,302,500
+4,300
+0.3% +$107K
ABCM
45
DELISTED
Abcam PLC
ABCM
$30.5M 0.79%
2,032,500
+412,000
+25% +$6.17M
MRSN
46
DELISTED
Mersana Therapeutics
MRSN
$27.6M 0.71%
163,038
– –
ACCD
47
DELISTED
Accolade Inc
ACCD
$26M 0.67%
2,274,000
+74,000
+3% +$807K
XLV icon
48
State Street Health Care Select Sector SPDR ETF
XLV
$44B
$24.2M 0.63%
200,000
– –
TVTX icon
49
Travere Therapeutics
TVTX
$5.74B
$23.4M 0.61%
951,650
– –
KYMR icon
50
Kymera Therapeutics
KYMR
$9.03B
$22.8M 0.59%
1,046,743
+270,864
+35% +$7.14M
1
2
3 4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, Rock Springs Capital Management held 133 positions worth $3.87B, up 13% from $3.44B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Rock Springs Capital Management deployed $144M of net new capital in Q3 2022, opening 4 new positions and adding to 60 existing holdings. Its largest new stake was Gossamer Bio: 1,586,962 shares worth $19M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier, followed by Consumer Staples and Industrials.

On the sell side, the largest reduction was Shockwave Medical, Inc. Common Stock, an estimated $15.4M trimmed.

  • Rock Springs Capital Management's largest Q3 2022 buy was Gossamer Bio: 1,586,962 shares worth $19M.
  • Rock Springs Capital Management added most to Immunocore in Q3 2022, an estimated $39.2M increase.
  • Rock Springs Capital Management's biggest Q3 2022 reduction was Shockwave Medical, Inc. Common Stock, cutting an estimated $15.4M.
  • Rock Springs Capital Management fully exited Sierra Oncology, Inc. Common Stock in Q3 2022, selling an estimated $64.6M.
  • Rock Springs Capital Management's ten largest holdings make up 35% of its $3.87B portfolio in Q3 2022.
  • Rock Springs Capital Management opened 4 new positions and closed 5 in Q3 2022.
  • Rock Springs Capital Management's portfolio value rose 13% quarter-over-quarter to $3.87B.

Based on Rock Springs Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.